{"type":"trials","record":{"id":42060,"source_id":"clinicaltrials-gov","external_id":"NCT06124677","title":"Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments","brief_summary":"The goal of this retrospective single-center chat review is to establish the efficacy and safety of a single dose of intravitreal faricimab (Vabysmo®) injection in patients with neovascular age-related macular degeneration (AMD), who were previously treated with aflibercept (Eylea®) and had persisting intraretinal or subretinal fluid despite frequent treatments.","overall_status":"Completed","phases":[],"study_type":"OBSERVATIONAL","sponsor":"Rigshospitalet, Denmark","enrollment":46,"countries":["Denmark"],"start_date":"2023-11-01","completion_date":"2023-12-01","last_update_date":"2023-12-11","source_url":"https://clinicaltrials.gov/study/NCT06124677","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years","comparator":null,"organization":"Rigshospitalet, Denmark","interventions":["Faricimab"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Proportion of patients responding to the treatment switch — 4 weeks","Durability of a single injection in cases of favorable treatment response without residual fluid — Up to 16 weeks","Differences in patient characteristics between individuals responding and not responding to faricimab — 4 weeks","Changes in visual acuity after the treatment switch — 4 weeks","Changes in central retinal thickness after the treatment switch — 4 weeks","Changes in pigment epithelium detachment (PED) height after the treatment switch — 4 weeks"],"design_description":null,"source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","Faricimab"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06124677","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-11-01 to 2023-12-01","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.914Z","intervention":["Faricimab"],"participants":46,"study_design":"OBSERVATIONAL","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Proportion of patients responding to the treatment switch — 4 weeks","Durability of a single injection in cases of favorable treatment response without residual fluid — Up to 16 weeks","Differences in patient characteristics between individuals responding and not responding to faricimab — 4 weeks","Changes in visual acuity after the treatment switch — 4 weeks","Changes in central retinal thickness after the treatment switch — 4 weeks","Changes in pigment epithelium detachment (PED) height after the treatment switch — 4 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as OBSERVATIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42060","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}